Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
40.29
+0.39 (0.98%)
Jan 17, 2025, 4:00 PM EST - Market closed
Revolution Medicines Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
| Revenue | 0.74 | 11.58 | 35.38 | 29.39 | 42.98 | 50.04 | Upgrade
|
| Revenue Growth (YoY) | -97.16% | -67.27% | 20.38% | -31.62% | -14.10% | 148.16% | Upgrade
|
| Cost of Revenue | 426.14 | 411.24 | 253.07 | 186.95 | 132.25 | 91.76 | Upgrade
|
| Gross Profit | -425.4 | -399.66 | -217.69 | -157.56 | -89.27 | -41.71 | Upgrade
|
| Selling, General & Admin | 87.73 | 62.02 | 40.59 | 30.45 | 21.43 | 12.41 | Upgrade
|
| Operating Expenses | 202.3 | 62.02 | 40.59 | 30.45 | 21.43 | 12.41 | Upgrade
|
| Operating Income | -627.7 | -461.69 | -258.28 | -188.01 | -110.7 | -54.12 | Upgrade
|
| Interest Expense | -0.3 | -0.3 | - | -0.01 | -0.07 | -0.11 | Upgrade
|
| Interest & Investment Income | 84.64 | 47.48 | 9.15 | 0.93 | 2.24 | 2.19 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.15 | 0.12 | - | - | - | - | Upgrade
|
| EBT Excluding Unusual Items | -541.22 | -414.39 | -249.13 | -187.09 | -108.53 | -52.04 | Upgrade
|
| Merger & Restructuring Charges | -25.5 | -25.5 | - | - | - | - | Upgrade
|
| Pretax Income | -566.72 | -439.89 | -249.13 | -187.09 | -108.53 | -52.04 | Upgrade
|
| Income Tax Expense | 0.34 | -3.52 | -0.42 | - | -0.37 | -4.37 | Upgrade
|
| Net Income | -567.06 | -436.37 | -248.71 | -187.09 | -108.16 | -47.66 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 2.22 | 14.24 | Upgrade
|
| Net Income to Common | -567.06 | -436.37 | -248.71 | -187.09 | -110.38 | -61.9 | Upgrade
|
| Shares Outstanding (Basic) | 160 | 113 | 81 | 73 | 55 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 160 | 113 | 81 | 73 | 55 | 3 | Upgrade
|
| Shares Change (YoY) | 59.41% | 40.34% | 10.74% | 32.68% | 1879.17% | 20.61% | Upgrade
|
| EPS (Basic) | -3.55 | -3.86 | -3.08 | -2.57 | -2.01 | -22.33 | Upgrade
|
| EPS (Diluted) | -3.56 | -3.86 | -3.08 | -2.57 | -2.01 | -22.33 | Upgrade
|
| Free Cash Flow | -551.11 | -358.3 | -235.22 | -153.71 | -103 | -52.21 | Upgrade
|
| Free Cash Flow Per Share | -3.45 | -3.17 | -2.92 | -2.11 | -1.88 | -18.83 | Upgrade
|
| Gross Margin | - | - | - | - | -207.68% | -83.36% | Upgrade
|
| Operating Margin | -84595.28% | -3986.92% | -730.01% | -639.70% | -257.54% | -108.15% | Upgrade
|
| Profit Margin | -76423.32% | -3768.28% | -702.95% | -636.58% | -256.79% | -123.70% | Upgrade
|
| Free Cash Flow Margin | -74273.85% | -3094.14% | -664.83% | -522.99% | -239.62% | -104.32% | Upgrade
|
| EBITDA | -621.56 | -456.68 | -254.34 | -184.96 | -108.12 | -51.88 | Upgrade
|
| EBITDA Margin | - | - | - | - | -251.54% | -103.67% | Upgrade
|
| D&A For EBITDA | 6.14 | 5.01 | 3.94 | 3.05 | 2.58 | 2.24 | Upgrade
|
| EBIT | -627.7 | -461.69 | -258.28 | -188.01 | -110.7 | -54.12 | Upgrade
|
| EBIT Margin | - | - | - | - | -257.54% | -108.15% | Upgrade
|
| Revenue as Reported | 0.74 | 11.58 | 35.38 | 29.39 | 42.98 | 50.04 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.